Examples of using Inducer in English and their translations into Croatian
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
Use: the goods to anti-estrogen fertility inducer, the objects in dysfunctional uterine bleeding,
Upotreba: roba na anti-estrogen plodnosti induktora, objekti u disfunkcionalnog krvarenja iz maternice,Rifampin, an inhibitor of OATPs and an inducer of CYP2C9, decreased lesinurad exposure
When patients are taking Intuniv concomitantly with a CYP3A4 inducer, an increase in the dose of Intuniv within the recommended dose range is proposed see section 4.2.
Kada bolesnici uzimaju Intuniv istovremeno s induktorom CYP3A4, predlaže se povišenje doze Intuniva unutar preporučenog raspona doza vidjeti dio 4.2.Co-administration of carbamazepine, a P-gp inducer, decreases tenofovir alafenamide plasma concentrations,
Istodobna primjena karbamazepina, induktora P-gp-a, smanjuje koncentracije tenofoviralafenamida u plazmi,Co-administration of cobimetinib with a strong CYP3A inducer was not assessed in a clinical study,
Istodobna primjena kobimetiniba sa snažnim induktorima CYP3A nije se ocjenjivala u kliničkom ispitivanju,rifampicin CYP3A4 inducer and modafinil may change the blood concentration of this product.
ketokonazol ili fenobarbital, induktor CYP3A4 rifampicina i modafinil mogu promijeniti koncentraciju ovog produkta u krvi.Co-administration of edoxaban with the P-gp inducer rifampicin led to a decrease in mean edoxaban AUC and a shortened half-life,
Istodobna primjena edoksabana s induktorom P-gp-a rifampicinom dovela je do smanjenja srednje vrijednosti AUC-aa strong CYP3A4 inducer, in 18 fasted healthy subjects,
snažnog induktora CYP3A4, u 18 zdravih ispitanika natašte,The concomitant use of fesoterodine with a potent CYP3A4 inducer(i.e. carbamazepine,
Ne preporučuje se istovremena primjena fesoterodina s jakim induktorima CYP3A4(tj. karbamazepinom,is not an inducer of CYP3A4 and CYP1A2.
2B6 te da nije induktor CYP3A4 i CYP1A2.a strong CYP3A inducer, decreased ivacaftor exposure(AUC) by 89%
jakim induktorom CYP3A, smanjila je izloženost ivakaftoru(AUC)Co-administration of St. John's wort, a P-gp inducer, may decrease tenofovir alafenamide plasma concentrations,
Istodobna primjena gospine trave, induktora P-gp-a, moţe smanjiti koncentracije tenofoviralafenamida u plazmi,In vivo, lesinurad is neither an inhibitor nor an inducer of CYP2C9 and 2C8, but a mild to moderate inducer of CYP3A.
In vivo, lesinurad nije ni inhibitor ni induktor CYP2C9 i 2C8, ali je blagi do umjereni induktor CYP3A.a strong CYP3A inducer, had minimal effect on the exposure of lumacaftor,
jakim induktorom CYP3A, minimalno je utjecala na izloženost lumakaftoru,Repeated administration of rifampin(600 mg once daily), a strong CYP3A inducer, resulted in an increase in cabazitaxel clearance of 21% corresponding to a decrease in AUC of 17.
Ponovljena primjena snažnog induktora CYP3A, rifampina,(600 mg jednom na dan) rezultirala je povećanjem klirensa kabazitaksela za 21%, što odgovara smanjenju AUC-a za 17.a potent inducer of CYP3A and CYP2B6, and an inducer of CYP2C9, CYP2C19,
snažan induktor CYP3A i CYP2B6 te induktor CYP2C9, CYP2C19Co-administration of rivaroxaban with the strong CYP3A4 inducer rifampicin led to an approximate 50% decrease in mean rivaroxaban AUC, with parallel decreases in its pharmacodynamic effects.
Istodobna primjena rivaroksabana s jakim induktorom CYP3A4 rifampicinom dovela je do smanjenja srednje vrijednosti AUC rivaroksabana za oko 50%, uz istodobno slabljenje njegovih farmakodinamičkih učinaka.a potent CYP3A4 inducer, the AUC of dasatinib was decreased by 82.
potentnog induktora CYP3A4, AUC dasatiniba smanjio se za 82.indicating that teriflunomide is not an inhibitor or an inducer of CYP2C9.
što upućuje na to da teriflunomid nije ni inhibitor ni induktor CYP2C9.Co-administration of strong cytochrome P450 3A4(CYP3A4) enzyme inducer, rifampicin, resulted in a reduction of systemic exposure of apremilast, which may result
Istodobna primjena s jakim induktorom enzima citokroma P450 3A4(CYP3A4), rifampicinom, rezultirala je smanjenjem sistemske izloženosti apremilastu,
